Luqa Pharma In-Licenses China Rights to Vitiligo Treatment

Luqa Pharma, a Shanghai in-licensing company with a focus on advanced dermatological treatments, acquired greater China rights from Laboratoires Genevrier for Viticell®, an innovative single-use kit that treats vitiligo. Vitiligo produces de-pigmented white patches on the skin. The condition, which is not contagious or life-threatening, cannot be cured, but it can be treated. In June, Luqa raised $15 million to advance its portfolio from Morningside Ventures. More details.... Share this with colleagues: // //